M42 buys into UK’s Juvenescence: Mubadala-backed healthtech investment firm M42 nabbed an undisclosed stake in UK-based biotech company Juvenescence, according to a press release. The transaction valued the longevity drug developer at just north of USD 550 mn.

The move expands M42’s portfolio into AI-powered anti-aging therapeutics and falls under the firm’s AI life sciences platform which it recently set up to tap AI tools for drug discovery.

REMEMBER- The company recently rolled out a new operating structure with four specialized platforms aimed at supporting growth and acquisitions: global patient care, AI life sciences, integrated health solutions, and digital health solutions.

About Juvenescence: Founded in 2016, the drug development company has raised roughly USD 214 mn to date across six funding rounds. Notable investors include Foresite Capital, Fast forward Innovations, Grok Ventures, and IDO investment.

Tags: